| DB ID | MyCo_5367 |
| Title | Serum Inflammatory Cytokine Markers of Invasive Fungal Infection in Previously Immunocompetent Battle Casualties |
| Year | 2015 |
| PMID | 26110227 |
| Fungal Diseases involved | Invasive fungal infection |
| Associated Medical Condition | battlefield traum |
| Genus | Scedosporium |
| Species | spp. |
| Organism | Scedosporium spp. |
| Ethical Statement | Institutional Review Board approval |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | RANTES |
| Biomarker Full Name | RANTES |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | USA |
| Cohort | After Institutional Review Board approval, we searched our prospectively collected Combat Trauma Registry to identify patients with histologically confirmed IFI infections. A cohort of patients without IFI was also identified with matched in jury pattern (blast and multiple amputations), age, and Injury Severity Scores (ISS). All study subjects were injured in combat operations abroad and were evacuated to our institution. |
| Cohort No. | None |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Angio-invasive fungal infections (IFI) are rare but devastating disease processes generally occurring in immunocompromised individuals with systemic diseases such as diabetes mellitus and acquired immune deficiency syndrome (AIDS), or those pharmacologically immunosuppressed to prevent transplanted organ rejection. However, after sustaining severe trauma (e.g., burns, farming accidents, natural disasters, etc.) previously immunocompetent individuals in whom IFI developed from Mucorales, Aspergillus, and Candida. These infections carry a high mortality rate regardless of immune status with 11%–38% mortality in trauma. |
| Technique | Analytic |
| Analysis Method | Multiplex platform proteomic analysis |
| ELISA kits | Human Cytokine 30-Plex Panel supplemented with a custom Human 2-plex Kit (Life Tech- nologies, Grand Island, NY). |
| Assay Data | None |
| Validation Techniques used | Multiplex platform proteomic analysis |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
